Xilio Therapeutics, Inc. (XLO) KPIs and segments
XLONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3080% below fair value
$7.54−0.16 (-2.08%)
Close on Nov 17, 2026Market cap $43.60MP/E –Yield –
KPIs & segments
Operating metrics and segments that drive Xilio Therapeutics's business
Coming soon
This tab will track the numbers specific to Xilio Therapeutics's business model — such as store count, revenue by banner, revenue per store and new openings — taken from filings and earnings releases.
See a number that looks wrong?